United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 9 mg in 1 ml - intravenous solutions containing sodium chloride are indicated for parenteral replenishment of fluid and sodium chloride as required by the clinical condition of the patient. none known. check flexible container solution composition, lot number, and expiry date. do not remove solution container from its overwrap until immediately before use. use sterile equipment and aseptic technique. to open - turn solution container over so that the text is face down. using the pre-cut corner tabs, peel open the overwrap and remove solution container. - check the solution container for leaks by squeezing firmly. if leaks are found, or if the seal is not intact, discard the solution. - do not use if the solution is cloudy or a precipitate is present. to add medication - identify white additive port with arrow pointing toward container. - immediately before injecting additives, break off white additive port cap with the arrow pointing toward container. - hold base of white additive port horizontally. - insert needle horizont

United States - English - NLM (National Library of Medicine)

jazz pharmaceuticals, inc. - sodium oxybate (unii: 7g33012534) (4-hydroxybutanoic acid - unii:30iw36w5b2) - sodium oxybate 0.5 g in 1 ml - xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy. xyrem is contraindicated for use in: risk summary there are no adequate data on the developmental risk associated with the use of sodium oxybate in pregnant women. oral administration of sodium oxybate to pregnant rats (150, 350, or 1,000 mg/kg/day) or rabbits (300, 600, or 1,200 mg/kg/day) throughout organogenesis produced no clear evidence of developmental toxicity; however, oral administration to rats throughout pregnancy and lactation resulted in increased stillbirths and decreased offspring postnatal viability and growth, at a clinically relevant dose [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. clinical considerations labor or d

United States - English - NLM (National Library of Medicine)

e. fougera & co., a division of nycomed us inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 g - sodium sulfacetamide medicated pads are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. sodium sulfacetamide medicated pads are contraindicated in persons with known or suspected hypersensitivity to sulfonamides or to any of the ingredients of the preparation. sodium sulfacetamide medicated pads are not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

acella pharmaceuticals, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 80 mg in 1 ml - sodium sulfacetamide 8% - sulfur 4% topical suspension is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. sodium sulfacetamide 8% - sulfur 4% topical suspension is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or ony other component of this preparation. sodium sulfacetamide 8% - sulfur 4% topical suspension is not to be used by patients with kidney disease. safety and effectiveness in children under the age of 12 have not been established.

United States - English - NLM (National Library of Medicine)

acella pharmaceuticals, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - sodium sulfacetamide 10% wash is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it is also indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. sodium sulfacetamide 10% wash is contraindicated for use by patients having known hypersensitivity to sulfonamides or any other component of this product. safety and effectiveness in children under the age of 12 have not been established.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - sodium ferric gluconate complex (unii: cc9149u2qx) (ferric cation - unii:91o4lml611) - ferric cation 12.5 mg in 1 ml - sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. - known hypersensitivity to sodium ferric gluconate or any of its components. pregnancy category b there are no adequate and well-controlled studies with sodium ferric gluconate complex in sucrose injection in pregnant women. reproduction studies have been performed in mice at doses up to 100 mg/kg/day (300 mg/m2 /day) and in rats at up to 20 mg/kg/day (120 mg/m2 /day). the doses in mice and rats are 4 and 1.5 times the human dose of 125 mg/day (77 mg/m2 /day) on a body surface area basis and have revealed no evidence of harm to the fetus due to sodium ferric gluconate complex in sucrose injection. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly ne

United States - English - NLM (National Library of Medicine)

rochester pharmaceuticals - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 90 mg in 1 g - sodium sulfacetamide 9% and sulfur 4.5% wash is indicated for the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. sodium sulfacetamide 9% and sulfur 4.5% wash is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sodium sulfacetamide 9% and sulfur 4.5% wash is not to be used by patients with kidney disease. safety and effectiveness in children under the age of 12 has not been established.

United States - English - NLM (National Library of Medicine)

trinity pharmaceuticals, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 9 mg in 1 g - sodium sulfacetamide 9% & sulfur 4.5% wash is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. sodium sulfacetamide 9% & sulfur 4.5% wash is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sodium sulfacetamide 9% & sulfur 4.5% wash is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 9 mg in 1 ml - this intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. this product is designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. consult prescribing information for indications and usage  of drug additives to be administered in this manner. this solution is contraindicated where the administration of sodium or chloride could be clinically detrimental.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

j c & a t searle pty ltd - dicamba present as the dimethylamine salt; mcpa present as the dimethylamine salt; bentazone as the sodium salt - aqueous concentrate - dicamba present as the dimethylamine salt benzoic acid-arylaliphatic active 19.0 g/l; mcpa present as the dimethylamine salt phenoxy acids-mcpa-amine active 112.0 g/l; bentazone as the sodium salt thiazole active 192.0 g/l - herbicide - lawn -see label for inclusion/exclusions | turf - bindy-eye | cat's ears or flatweeds | chickweed | clover | creeping oxalis | cudweed | dandelion - taraxacum officinale | dock | fleabane | mullumbimby couch | ribwort, ribgrass or lamb's tongue | sowthistles | annual flatweed | bindii | bogan flea | broadleaf dock | calotis hispidula | clover sorrel | common chickweed | common dandelion | common plantain | corn sowthistle | curled dock | english dandelion | european dandelion | jo-jo | narrow leaf plantain | onehunga weed | perennial flatweed | perennial sow thistle | rumex brownii | rumex crispus | rumex obtusifolius | small-leaved oxalis | sonchus arvensis | sonchus asper | sonchus oleraceus | sow thistles | star burr | taraxacum spp. | true dandelion | wood sorrel (yellow) | yellow wood sorrel